July 23, 2021
Anivive’s GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment
The PNAS article “Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection” describes a study that shows that mice with fatal SARS-CoV-2 infections have a decreased and improved viral load Survival was shown when treated with deuterated variants of GC376, an antiviral drug developed by Anivive Lifesciences. All coronaviruses, including SARS-CoV-2, contain a protease …